SpeedWeed

MAY 18, 2021

Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. cannabis researchers. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis.

DEA 52

DEA Research and Development Data Cannabis 52

Cannabis Law Report

JUNE 10, 2021

(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

The Blunt Truth

SEPTEMBER 10, 2021

The DEA would like to increase the production quota for marijuana used for research. The Drug Enforcement Agency (DEA) called for an increase in marijuana production. They need to ramp up research to aid in the development of new FDA-approved drugs. More research means a lot more product.

Research and Development 124

Research and Development DEA Consumption State Laws 124

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 51

DEA Clinical Trials THC Research and Development 51

SpeedWeed

MAY 22, 2021

After years of delays, legal challenges, and obfuscation, the US Drug Enforcement Agency (DEA) finally announced that it would begin evaluating applications for federally-licensed research cannabis cultivators. . In 2019, a federal judge forced the DEA to explain its inaction.

DEA 52

DEA Cultivation Research and Development Cannabis 52

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. “DEA

DEA 52

DEA Research and Development Clinical Trials Extraction 52

FloridaMarijuana.net

JULY 8, 2018

The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. The psychological symptoms that develop because of the trauma affect mood, cognition, memories (both suppression and the inability to form new memories) and physical health.

Strains 190

Strains Indica Hybrid Research and Development 190

Cannabis Law Report

JUNE 29, 2021

In recent months, the DEA has issued a select number of licenses to several groups in the US to allow for the cultivation of Cannabis for scientific research purposes. BRC works with research groups studying Cannabis and Cannabis flower to understand the plant in a scientific and federally regulated environment.

Research and Development 102

Research and Development DEA Supply Chain Pharmaceutical 102

SpeedWeed

MAY 24, 2021

The Drug Enforcement Administration made a milestone announcement earlier this month with the news that the DEA will begin granting marijuana cultivation licenses to various third-party applicants, significantly expanding medical and scientific cannabis research in the United States.

DEA 52

DEA Cultivation Research and Development Marijuana 52

Cannabis Law Report

NOVEMBER 5, 2021

Cybin Granted DEA Schedule I Manufacturing License. Drug Enforcement Agency (“DEA”). The DEA license is a federal requirement for any investigators who intend to study, produce, analyze or otherwise work with Schedule I controlled substances. The DEA license is for the Company’s research lab in the Boston area.

DEA 52

DEA Research and Development Programs Media 52

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. The partnership will initiate the development of CBD and THC oral thin films for CURE’s clinical studies targeted at advancing veteran health.

DEA 45

DEA Pharmaceutical Research and Development Compliance 45

Cannabis Law Report

JULY 27, 2021

The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. organization to help advance scientific research into the potential medical benefits of cannabinoids.

Research and Development 76

Research and Development Pharmaceutical Sativa Extraction 76

SpeedWeed

AUGUST 7, 2021

Democratic leaders in both chambers of Congress have come up with a new plan that would make it easier for scientists to access high-quality cannabis for research. . The provision would require the US transportation secretary to develop a public report on the risk of cannabis-impaired driving within two years of the bill’s passage.

DEA 52

DEA Research and Development Legalization Strains 52

Veriheal

JUNE 29, 2021

Did we ever stop to think that if we could legally utilize the plants in the first place that perhaps we wouldn’t develop terminal illnesses at such a high rate? The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws. Introducing the Right to Try Act.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Cannabis Law Report

JANUARY 10, 2022

Panacea”), a leading United States biotechnology company focused on developing new therapeutic, cultivation, extraction and isolation techniques for high value natural products such as psychedelic-containing lifeforms and cannabis. is a Canadian biotechnology company providing cannabis testing and research services.

Research and Development 52

Research and Development Supply Chain DEA Events 52

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.

CBD 105

CBD Research and Development DEA Hemp 105

Cannabis Law Report

NOVEMBER 17, 2022

This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp.

Research and Development 52

Research and Development Pharmaceutical DEA Cannabinoids 52

Cannabis Law Report

DECEMBER 15, 2021

Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin-containing mushrooms for authorized research purposes. market for research purposes is absolutely key for us as we look to expand our business in 2022,” he adds. “With their track-record of working with the U.S.

Supply Chain 52

Supply Chain Research and Development DEA Pharmaceutical 52

Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

The Blunt Truth

MAY 15, 2020

We’ve got an update on the latest Montana legalization developments. marijuana research. We reported last week on the DOJ’s memo finding that the Drug Enforcement Administration’s cannabis research program is non-compliant with international drug laws. SBA funds, however, are not. montana update.

Banking 106

Banking Research and Development Programs Advocacy 106

Canna Law Blog

MARCH 4, 2020

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).

Legalization 115

Legalization Therapy Chronic Pain DEA 115

Cannabis Law Report

JULY 6, 2021

The Congressional Research Service (CRS) released a report which says there are “three leading markets for hemp, each based on the part of the plant used: fiber, seed/grain, and flower.” The FDA has jurisdiction over the area and hasn’t developed rules allowing for CBD products in the food supply. Marijuana Moment.

Hemp 81

Hemp CBD DEA Legalization 81

Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.

Research and Development 102

Research and Development Therapy Consumption DEA 102

SpeedWeed

MARCH 21, 2021

Trulieve offers Delta-8 in its TruPod vaporizer cartridges and TruClear Syringes, says Beau Williamson, Trulieve director of research and development. Delta-8 is psychoactive, Russo says, though he adds that more research is needed to better understand its effect on humans. That is totally wrong.”. RELATED: U.S.

Research and Development 40

Research and Development Hydroponic DEA Cannabinoids 40

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

MAY 13, 2022

According to the Drug Enforcement Administration (DEA) website , magic mushrooms are recognizable by their slender stems, which are “topped by caps with dark gills on the underside.” has funneled her energy into simplifying the process of conducting psychedelic research. Research efforts are ongoing. milligrams.

Research and Development 98

Research and Development Legalization Consumption Microdosing 98

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?

Law 81

Law Research and Development Therapy DEA 81

Veriheal

MARCH 6, 2024

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The other big change that comes with rescheduling is an increase in cannabis research opportunities. billion in excess taxes when compared to non-cannabis businesses.

Research and Development 64

Research and Development DEA Chronic Pain Business 64

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits.

Legalization 111

Legalization Medicine Decriminalization Research and Development 111

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level.

Law 81

Law Therapy Clinical Trials Research and Development 81

Cannabis Law Report

MARCH 18, 2022

Husch Blackwell has launched its Psychedelics and Emerging Therapie s team, an interdisciplinary, cross-office group of lawyers capable of addressing the challenges faced by innovators that seek to research, develop and commercialize novel therapies based on psychedelic drugs. Steve Levine.

Therapy 52

Therapy Research and Development Clinical Trials Environment 52

SpeedWeed

AUGUST 12, 2021

Our latest research empowers us with new insights to assess each grower’s objectives, weigh those objectives against a facility’s unique financial, environmental and energy parameters, and then ultimately derive a tailored solution for each cultivator.”. Merlice tomatoes. Second, watch your red light ratio.

DEA 40

DEA Research and Development Hemp Cultivation 40

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. The Next Move Is On The DEA. FDA Grants Approval of Epidiolex.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JANUARY 23, 2020

This paper shall give a condensed overview over the status quo in Thailand and the potential emerging from the ongoing developments.” This paper shall give a condensed overview over the status quo in Thailand and the potential emerging from the ongoing developments. $16. It can be downloaded at: [link]. cannabis programm. $4b.

Research and Development 59

Research and Development Oil Cultivation DEA 59

Medicinal Genomics

JULY 13, 2023

So here are just a dozen new developments, breakthroughs, and aha moments from this year’s summit that might just convince you to circle CannMed 24 on your calendar right now. the VP of Research & Development at Biopharmaceutical Research Company, Inc., But if you weren’t able to be there, you wouldn’t know that.

Research and Development 52

Research and Development Cannabinoids Medicine DEA 52